Free Trial
NASDAQ:PULM

Pulmatrix (PULM) Stock Price, News & Analysis

Pulmatrix logo
$8.92 -0.09 (-1.00%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$9.10 +0.18 (+1.96%)
As of 02/21/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pulmatrix Stock (NASDAQ:PULM)

Key Stats

Today's Range
$8.81
$9.35
50-Day Range
$5.76
$10.02
52-Week Range
$1.55
$10.40
Volume
20,434 shs
Average Volume
35,780 shs
Market Capitalization
$32.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Pulmatrix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
2nd Percentile Overall Score

PULM MarketRank™: 

Pulmatrix scored higher than 2% of companies evaluated by MarketBeat, and ranked 953rd out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pulmatrix.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pulmatrix is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pulmatrix is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pulmatrix has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pulmatrix's valuation and earnings.
  • Percentage of Shares Shorted

    1.45% of the float of Pulmatrix has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmatrix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmatrix has recently increased by 10.90%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pulmatrix does not currently pay a dividend.

  • Dividend Growth

    Pulmatrix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.45% of the float of Pulmatrix has been sold short.
  • Short Interest Ratio / Days to Cover

    Pulmatrix has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pulmatrix has recently increased by 10.90%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    4 people have searched for PULM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pulmatrix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.62% of the stock of Pulmatrix is held by insiders.

  • Percentage Held by Institutions

    Only 11.84% of the stock of Pulmatrix is held by institutions.

  • Read more about Pulmatrix's insider trading history.
Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

PULM Stock News Headlines

$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
Pulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed Merger
Pulmatrix Shares Surge on Merger with Cullgen
See More Headlines

PULM Stock Analysis - Frequently Asked Questions

Pulmatrix's stock was trading at $6.98 at the beginning of the year. Since then, PULM shares have increased by 27.8% and is now trading at $8.92.
View the best growth stocks for 2025 here
.

Pulmatrix, Inc. (NASDAQ:PULM) posted its earnings results on Friday, November, 8th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.37 million for the quarter. Pulmatrix had a negative trailing twelve-month return on equity of 45.97% and a negative net margin of 96.51%.

Shares of Pulmatrix reverse split before market open on Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional investors of Pulmatrix include Renaissance Technologies LLC (2.99%), SBI Securities Co. Ltd. (1.81%), Geode Capital Management LLC (1.01%) and Concourse Financial Group Securities Inc..
View institutional ownership trends
.

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), General Electric (GE), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

Last Earnings
11/08/2024
Today
2/22/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PULM
Employees
20
Year Founded
N/A

Profitability

Net Income
$-14,120,000.00
Pretax Margin
-96.51%

Debt

Sales & Book Value

Annual Sales
$7.30 million
Book Value
$4.93 per share

Miscellaneous

Free Float
3,629,000
Market Cap
$32.56 million
Optionable
Not Optionable
Beta
1.61

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:PULM) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners